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Keypoints: Both binding and neutralizing heterosubtypic antibodies to non-human 
influenza A isolates can be found in most individuals. Their development is favored by age 
and frequent vaccination. Original antigenic sin was found to imprint but not to impair the 
homotypic antibody response.   
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Summary  
Heterosubtypic antibodies to influenza A virus will be crucial for the development of a pan-
influenza vaccine. Here we show that most individuals already possess heterosubtypic 
antibodies and that their generation is favored both by vaccination and age. 
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Abstract  
Background: The effectiveness of trivalent influenza vaccination has been confirmed in 
several studies. To date, it is not known whether repeated exposure and vaccination to 
influenza promote production of cross-reactive antibodies. Further, how strains encountered 
earlier in life imprint the immune response is currently poorly understood. 
Methods: To determine the prevalence for human homo- and heterosubtypic antibody 
responses, we scrutinized serum samples from 305 healthy volunteers for hemagglutinin-
binding and -neutralizing antibodies against several strains and subtypes of influenza A. 
Statistical analyses were then performed to establish the association of measured values with 
potential predictors.  
Results: It was found that vaccination not only promoted higher binding and neutralizing 
antibody titers to homosubtypic influenza isolates but also increased heterosubtypic human 
immune responses. Both binding and neutralizing antibody titers in relation with age of the 
donors mirrored the course of the different influenza strain circulation during the last 
century. Advanced age appeared to be of advantage for both binding and neutralizing titers 
to most subtypes. In contrast, the first virus subtype encountered was found to imprint to 
some degree subsequent antibody responses. Antibodies to recent strains, however, 
primarily seemed to be promoted by vaccination. 
Conclusion: We provide evidence that vaccinations stimulate both homo and heterosubtypic 
immune responses not only in young and middle-aged, but also in more senior individuals. 
Our analyses suggest that influenza vaccinations not only prevent infection against currently 
circulating strains but can also stimulate broader humoral immune responses that 
potentially attenuate infections with zoonotic or antigenically shifted strains.  
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Background 
The antibody response to influenza viruses is highly strain- and subtype-specific, and is 
primarily directed against the variable immunodominant apical epitopes on the 
hemagglutinin (HA) protein [1]. Vaccine-induced antibodies are therefore only effective 
against viruses closely related to the inoculated strains, and immunization needs to be 
revised annually in order to reflect the antigenic outfit of the viruses predicted to be 
predominant in the following influenza season. The breadth of the anti-influenza virus 
antibody response is further limited by the original antigenic sin (OAS) in that every 
immunization also boosts the memory response to the priming strain [2]. Indeed, Lessler 
and colleagues stated that in humans repeated exposure to different H3N2 strains increased 
antibody titers to strains encountered earlier in life [3]. 
Heterosubtypic antibodies, i.e. antibodies recognizing hemagglutinins from different 
subtypes, are rare [4]: in human pre-vaccination sera, only 0·01% of total serum IgG has 
been described to have heterosubtypic binding activity, one tenth of which being specific for 
the HA stem-epitope [4-6]. To establish the prevalence and predictors for heterosubtypic 
antibody responses, serum from 305 HIV-negative volunteers was collected in October 
2009. In these sera we assessed both binding to five human and three non-human influenza 
isolates, and neutralizing antibody titers to five human and four non-human influenza 
isolates. These data were put into relation with epidemiological information acquired with a 
questionnaire at the blood draw.  
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Methods 
Procedures 
Sera from 305 randomly selected healthy volunteers were prospectively collected in Zurich, 
Switzerland, in late 2008 before the arrival of the H1N1 pandemic (H1pdm/09). The study 
was approved by the ethics committee of the University Hospital Zurich and written 
informed consent was obtained from all study participants. Self-reported demographic data 
including age, sex, travel history, the total number of estimated previous influenza 
vaccinations, estimated times of influenza infections (defined as ‘flu’ with more than three 
bedridden days and high fever), and potential contact to influenza-infected birds were 
collected on the day of the blood draft (an English translation of the questionnaire is given in 
the supplementary methods section). As antibodies binding to avian or extinct human HA 
subtypes are bona-fide cross-reactive, we determined binding antibody titers to recombinant 
trimeric HA protein from rH1pdm/09, rH2/57, rH4/56, rH5/04, rH7/79 and rH12/76 by 
ELISA and put them into relation to homotypic antibodies to rH1/34 and rH3/99. In 
addition, we assessed whether antibodies binding to recombinant protein can also bind 
immobilized purified H7N7 virions (H7vir/79, suppl. figure 3). The half-maximal effective 
dose (EC50) was then determined by non-linear regression of optical density (OD) values, 
and used for statistical analyses as well as to establish correlations with the information 
collected in questionnaire.  
Strains used for neutralization assays are described in the supplementary data. For 
evaluation, the reciprocal 50% inhibitory dose was determined by non-linear regression to 
the logarithm of serum concentration (-log(IC50)), where possible. If most samples did not 
reach signal saturation, and constrained non-linear regression would have been prone for 
fitting artifacts, the inhibition percentage at the second serum dilution (1:90) was taken as a 
surrogate value. Statistical analyses were performed as outlined in the supplementary 
methods. R scripts used for this study are available at https://github.com/ozagordi/FluAbs. 
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Results 
For the analysis of the prevalence and predictors of heterosubtypic antibodies, a random 
study population was compiled (n=305; table 1). At a serum dilution corresponding to the 
detection level of natural antibodies [7] and a relaxed threshold (threefold over background), 
between 99% and 100% of individuals, depending on the antigen tested, scored positive for 
serum antibodies binding, including all heterosubtypic HAs. Also at more stringent 
conditions of 1 in 90, 98-100% of individuals scored positive. If a more stringent threshold of 
a half-maximal signal was applied, heterosubtypic specificity could be monitored in 32-99% 
(at 1 in 30) and 0·3-79% (at 1 in 90) of the participants. The corresponding values are 
depicted in suppl. figure 1. 
With the exception of rH12/76, binding titers to the avian strains (rH4/56, rH5/04 and 
rH7/79) were low compared to human HAs. Low titers were also observed against 
rH1pdm/09 that had not yet arrived in Switzerland when the blood was collected. Titers 
against human rH2/57 that became extinct in 1968 were also found to be relatively low, 
although distributed over a wide range of values.  
To determine the direct antiviral activity of these antibodies we performed in vitro 
neutralization assays against H1/34, H1/07, H2/57, H3/07, H3/68, H4/56, H5/04 and 
H7/79 viruses. The highest neutralizing titers were found against homologous human strains 
(H1/34, H1/07, H2/57, H3/68 and H3/07; suppl. figure 1C and table S1). Titers to avian 
H4/56 were much lower and the barely detectable neutralizing activity to H5 and H7 even 
prevented computation of the logIC50 values. Instead, the percentage of inhibition at the first 
dilution (1 in 90) was taken as comparative proxy value for these viruses (suppl. figure 1D). 
ELISA titers and neutralizing activity correlated well in that high titers in ELISA are 
indicative for high neutralizing activity (table S2). Vaccinated individuals clearly displayed 
higher binding and neutralizing titers against human subtypes H1/34, while still showing 
increased titers against rH2/57, rH3/99 and H3/68 (figure 1 and 2), albeit less markedly. As 
highlighted in the regression analysis, some of these differences may be explained by age 
alone (table 2). Vaccinated individuals also displayed significantly higher neutralizing titers 
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against H1/07 and H3/07 than non-vaccinated individuals. They also displayed higher 
binding antibody titers to heterosubtypic rH1pdm/09 and rH5/04 (figure 1). Vaccination 
showed no or weaker effect on binding titers against the remaining three tested 
heterosubtypic rHAs. 
The effect of age, influenza episodes and gender was also analyzed (table 3 and 4). As an 
exploratory data analysis, we stratified the age in three different categories according to the 
different influenza pandemics [baseline: born 1969-2009 (age 0-40), category 1: 1958-1968 
(age 41-51), category 2: 1919-1957 (age 52-90)]. After adjusting the model for age, influenza 
episodes and gender, vaccination still remained a predictor for higher binding and 
neutralizing titers to the same subtypes as in the two-sample t test. However, the impact of 
vaccination was lost for rH2/57 binding and H3/68 neutralizing titers in the adjusted 
models (table 3 and 4).  
We then performed linear regression to correlate the age of donors and the vaccination 
status with binding and neutralizing antibody titers (suppl. figures 2 and table 2). 
Binding titers to human strains all increased with age, while increasing only in two out of five 
non-human strains, all of these phylogenetically close to the human ones (H1pdm/09 and 
H5/04). Neutralizing titers were also found to increase with age in two out of five human 
strains tested (H2/57 and H3/68). On the other hand, titers to heterosubtypic strains did not 
display a dependence on age. 
Similarly, vaccination showed a positive correlation in binding and neutralizing titers to 
most human strains, with the exception of the neutralizing titers to H3/68, which were 
independent of vaccination (figure 3, table 2). Titers to H2/57 were distinct, as binding titers 
did not depend on vaccination, and neutralizing titers showed a modest interaction between 
age and vaccination status. Specifically, neutralizing titers to H2/57 increased with age for 
both vaccinated and non-vaccinated groups, but were more pronounced in the vaccinated 
group. As both H2 and H5 subtypes have never been included in the vaccines, the fact that 
vaccination had a positive correlation with neutralizing titers to these subtypes can be 
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explained by their phylogenetic proximity to H1 subtype, which is part of the widely used 
split vaccine formulation. 
In order to expose differences between age groups that would go undetected in linear 
regression, we performed loess smoothing on antibody titers in relation to age separately for 
vaccinated and non-vaccinated donors. Neutralizing titers to recent human isolates (H1/07 
and H3/07) were higher in vaccinees, but overall not influenced by age (as already suggested 
by linear regression). However, non-linear regression revealed that the youngest 
participating donors (approximately below age 30) clearly showed the highest titers (figure 
3). Similar findings were made for binding titers to recently isolated H3/99. This was in 
contrast to the behavior observed against older isolates (H2/57 and H3/68); here the best 
neutralizing titers were found in those donors who were in their first decade of life when the 
corresponding isolate has been circulating (age 50 to 61 and age 41 to 50, respectively). The 
same trend emerged for binding titers to H2/57. On the other hand, for an older H1 isolate 
(H1/34) this effect was less pronounced for both neutralizing and binding titers. 
 
Discussion 
Our study demonstrates that heterosubtypic antibodies against influenza viruses, i. e. 
antibodies recognizing hemagglutinin from multiple subtypes, can be found in most exposed 
or immunized individuals. These findings corroborate previous findings made by 
biochemical analysis of a limited number of samples [4, 8]. We have found that vaccination 
not only enhanced antibody responses to subtypes that are currently circulating, and are 
therefore included in the vaccine, but also augmented binding and neutralizing antibody 
titers to heterosubtypic subtypes. Senior people had higher antibody titers to old 
homosubtypic influenza isolates than their younger counterparts, whose antibody response 
appeared to favor more recent isolates. Age was also found to be a predictor with a positive 
coefficient for higher antibody titers to heterosubtypic isolates. In contrast, the number of 
self-reported influenza episodes did not correlate with higher antibody titers, which, given 
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the unreliability of the parameter, is not surprising. Moreover, since vaccinations, like 
influenza episodes, also accumulate with age and may not always be reported accurately, it is 
hard to disentangle their effect on the antibody titers. For this reason, vaccination status was 
reported as binary (vaccinated/non vaccinated), discarding differences in the number of 
vaccinations.  
As the participants of our study have not recently been vaccinated, their antibody repertoire 
is not skewed towards a recently inoculated vaccine-strain. Attention is therefore focused on 
the serum antibody composition present when infection is most likely to occur. The use of 
viable viruses for neutralization assays rather than highly-neutralization sensitive 
pseudotyped virions further assured that the neutralizing activity detected is biologically 
relevant [9].  
At the time of serum sampling, H1pdm/09 had not yet reached Switzerland. Potential 
H1pdm/09-related induction of broadly cross-reactive antibodies [10] is therefore unlikely 
to have skewed our results. Yet, our data is consistent with findings that H1pdm/09 
possesses an epitope that is shared with the H1N1 virus strains circulating before 1957: 
individuals born before 1957 had higher titers to H1pdm/09 than younger participants [11, 
12]. Although the binding titers were expected to increase with age in the non-vaccinated 
cohort, no peak in elderly appeared in non-parametric smoothing. Both observations, 
however, could be explained by the low sample size in this age group (figure 3).  
Since we used a novel neutralization assay we cannot give predictions for protection. In the 
hemagglutinin inhibition assays (HIA), a serum dilution of 1 in 40 is considered protective 
while comparable values were found for an ELISA-based and a colorimetric 
microneutralization assay (MN) but these values are not applicable to our assay [13] in 
particular since it was also shown that ELISA values and HIA values do not correlate, not 
even within the same subtypes [14]. Moreover, since the majority of heterosubtypic 
antibodies was found to bind a conserved epitope in the stem of the HA protein and did not 
interfere with hemagglutination [15, 16], they would not be detected by HIA. Consequently, 
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no direct predictions for heterosubtypic protection can be drawn from our dataset at this 
point. Further research will be required to define this relationship. 
In contrast, the large number of serum samples tested for both binding and neutralization 
allowed us the establishment of a linear relationship: increasing titers of binding antibodies 
correlate statistically significant with increasing neutralizing titers (table S2). The correlation 
coefficient R for extinct human strains was reasonable high especially in rH2/57 vs. H2/57 
(R=0·43), whereas isolates with very distant isolation years, H3/68 vs. rH3/99 did not 
correlate at all, despite belonging to the same subtype.  
Lessler and colleagues found that repeated exposure to different H3N2 strains increased 
antibody titers to those strains encountered earlier in life while progressively fewer specific 
antibodies to subsequent infection are made with age [3]. We could confirm this finding in 
that the neutralizing and binding titers were the highest in those individuals who were in 
their first decade of life during the period of time when the corresponding subtype was 
circulating. Older individuals also had significantly more binding and neutralizing antibodies 
against old than more recent isolates (e.g. H3/99; suppl. figure 2), which may reflect original 
antigenic sin [17]. In contrast, in line with other studies [18] we found antibody titers to the 
last pre-study isolates (’07) to be the same in all age groups.  
In elderly individuals, vaccination increased the probability of having heterosubtypic 
antibodies. Thus, while senescence of the immune system presumably contributed to a 
poorer response to recent isolates, age was advantageous for the development of 
heterosubtypic antibodies (to both human and non-human isolates). Vaccination always 
improved titers in the oldest or middle age group compared to young individuals. Although 
the age at which the vaccinations were received was not assessed, most individuals received 
them in the previous 5-10 years. In fact, influenza vaccination was very uncommon in 
Switzerland prior to the late nineties. [19]. Our findings show that vaccination is of value also 
in more seasoned individuals, and that its benefit is not just the result of vaccinations at 
younger age. This provides additional, albeit indirect, support for annual vaccinations in 
elderly. 
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Although most humans have low levels of heterosubtypic antibodies, they are still 
susceptible to infection with antigenically drifted or shifted influenza A strains, indicating 
that these antibodies probably are not protective. Yet such antibodies are likely to attenuate 
disease but, to prove this hypothesis, large clinical trials would need to be conducted. The 
findings of our study nonetheless clearly indicate that novel vaccination strategies targeting 
the conserved epitopes of influenza hemagglutinin could profit from pre-existing antigen-
experienced heterosubtypic B cells. Our data also unambiguously support yearly vaccination 
as neutralizing antibody titers increase over time in elderly and younger people and 
furthermore, more heterosubtypic antibodies are induced. 
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Figure legends 
Figure 1. Vaccination-dependent differences in -log(EC50) titers against 
recombinant human and avian influenza hemagglutinin. Serum antibody 
reactivities to the indicated immobilized recombinant hemagglutinin were assessed by 
ELISA. Two-sample t test analyses of the data were performed and showed higher binding 
antibody titers to the human subtypes rH1/34 and rH3/99, to heterosubtypic rH1pdm/09, 
rH2/57 and to avian heterosubtypic rH5/04 titers in the vaccinated cohort. Values are shown 
as logarithm of the reciprocal serum dilution giving a half-maximal signal (-logEC50). Median 
and p-values of each group are indicated by numbers. Boxplots represent median and IQR, 
whiskers depict lower or upper quartile ± 1·5 x IQR. 
Figure 2. Differences in serum half-maximal inhibitory titer -log(IC50) in 
vaccinated and non-vaccinated individuals against human and avian influenza 
subtypes. Serum antibody neutralizations against the indicated viral subtypes were 
assessed in neutralization assays. Two sample t-test analysis were performed and showed 
higher neutralizing antibody titers to all homotypic viruses (H1/07, H1/34, H3/68 and 
H3/07) and to heterosubtypic avian virus H5/04 in the vaccinated cohort. No improvement 
in titers for human heterosubtypic H2/57 and for avian H4/56 or H7/79 viruses was found. 
Neutralizing data from figure 1 was used for this analysis. Values are shown as logarithm of 
the reciprocal serum dilution giving a half-maximal inhibitory concentration, and as 
inhibition percentage against H5/57 and H7/79 at a serum dilution of 1 in 90. Median and p-
values are indicated. Boxplots indicate median and IQR. Whiskers include lower or upper 
quartile ± 1·5 x IQR. 
Figure 3: Loess smoothing of antibody titers. (A) The binding antibody titers for 
rH3/99, but not for rH1/34 or rH2/57, were lower in more seasoned individuals. Smoothing 
discovers steep increase of -log(EC50) around age 40 for rH2/57. For rH1/34, smoothing 
displayed results similar to linear regression. Highest -log(EC50) titers to rH3/99 are 
depicted in the age group of the 21-27 years old individuals. Values are shown as logarithm 
of the reciprocal serum dilution in correlation with age. (B) Neutralizing titers to H1/34 
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(vaccinated), H2/57 (vaccinated and non-vaccinated) and H3/68 (vaccinated and non-
vaccinated) increased with increasing age. -log(IC50) to H1/07 (vaccinated) decreased with 
increasing age (cf. suppl. figure 2). Remaining subtypes do not show slopes different from 
zero. Smoothing of -log(IC50) for H2/57 discovered a peak at age 50. Values are shown as 
logarithm of the reciprocal serum dilution giving a half-maximal inhibitory concentration in 
correlation with age, and, separated by bold frame lines, as inhibition percentage against 
H5/57 and H7/79 at a serum dilution of 1 in 90. Blue triangles and lines represent the 
vaccinated, black squares and lines the non-vaccinated cohort. Grey shaded areas indicate 
the confidence band. Significance codes (testing the slope being different from zero): *** 
p<0·001, ** p<0·01, * p<0·05. 
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Table 1. Cohort characteristics  
 
Total	  study	  participants	  included	  in	  the	  study	  (n)	  	   305	  
	   	  
Gender	  (female)	   156	  (51·∙15%)	  
Median	  age	  [interquartile	  range	  (IQR)]	   36	  [28-­‐49]	  
Median	  vaccinations	  [IQR]	   2	  [0-­‐5]	  
Median	  episodes	  [IQR]	   2	  [0-­‐3]	  
Contact	  to	  FPV-­‐infected	  poultry	   3	  (0·∙98%)	  
Travel	  to	  rural	  region	  in	  southeastern	  Asia	   23	  (7·∙54%)	  
Novartis	  vaccine	  trial	   17	  (excluded)	  
Swine	  flu	  (H1pdm/09)	  infection	   0	  
 
 
 
Table 2. Linear regression analyzing the impact of age and vaccination on binding 
and neutralizing antibody titers. 
 
 
 
 
rHAs,	  recombinant	  hemagglutinin.	  
 
Binding titers -log(EC50) and neutralizing titers -log(IC50) were modeled as a linear 
function of age, vaccination and their interaction (intercept  +  α × age  +  β × 
vaccination  +  γ × age × vaccination). The age is given in years and vaccination is a 
binary dummy variable. Starting from the complete model, coefficients not 
significantly differ from zero (at the 1% level) were dropped and the model estimated 
again. The table reports the parameter estimates for the final model. Where no effect 
of age and/or vaccination was detected, median and interquartile range are reported 
in the intercept column. 
 
	  Linear	  regression	  analyzing	  the	  impact	  of	  age	  and	  vaccination	  on	  binding	  titers	  -­‐log(EC50)	  and	  neutralizing	  titers	  -­‐log(IC50)	  
	  
Subtype	   	  	   rHAs	  and	  strains	   Intercept	   Age	  (α)	   Vaccination	  (β)	   Interaction	  (γ)	  
Hu
m
an
	  
Binding	  
rH1/34	   1·∙80	  ±	  0·∙067	   0·∙0081	  ±	  0·∙0017	   0·∙33	  ±	  0·∙041	   	  	  
rH2/57	   	   0·∙029	  ±	  0·∙0007	   	   	  	  
rH3/99	   3·∙58	  ±	  0·∙099	   -­‐0·∙0096	  ±	  0·∙0025	   0·∙21	  ±	  0·∙062	   	  	  
Neutralization	  
H1/34	   2·∙92	  ±	  0·∙043	   	  	   0·∙21	  ±	  0·∙054	   	  	  
H1/07	   2·∙34	  ±	  0·∙070	   	   0·∙54	  ±	  0·∙087	   	  	  
H2/57	   1·∙83	  ±	  0·∙12	   0·∙019	  ±	  0·∙0032	   -­‐0·∙55	  ±	  0·∙16	   0·∙012	  ±	  0·∙0040	  
H3/68	   1·∙64	  ±	  0·∙097	   0·∙027	  ±	  0·∙0024	   	   	  	  
H3/07	   2·∙47	  ±	  0·∙065	   	  	   0·∙24	  ±	  0·∙082	   	  	  
He
te
ro
su
bt
yp
es
	  
Binding	  
rH1pdm/09	   1·∙19	  ±	  0·∙065	   0·∙0047	  ±	  0·∙0016	   0·∙18	  ±	  0·∙041	   	  	  
rH4/56	   1·∙62	  ±	  0·∙68	   	   	   	  	  
rH5/04	   0·∙93	  ±	  0·∙099	   0·∙013	  ±	  0·∙0025	   0·∙27	  ±	  0·∙062	   	  	  
rH7/79	   1·∙64	  ±	  0·∙36	   	   	   	  	  
rH12/76	   2·∙22	  ±	  0·∙62	   	  	   	  	   	  	  
Neutralization	  
H5/04	   1·∙36	  ±	  1·∙05	   	  	   3·∙62	  ±	  1·∙34	   	  	  
H7/79	   11·∙5	  ±	  17·∙5	   	  	   	  	   	  	  
Table 3. Analysis of binding titers with respect to age group and vaccination status. 
 
Table	  3.	  Multivariable	  regressions	  analyzing	  binding	  titers	  -­‐log(EC50)	  in	  
relation	  with	  vaccination	  and	  age.	  
	   	   	   	  
rHA Characteristics Regression	  Coefficient	  
(95%	  CI) 
p-­‐value 
rH1/34 Vaccination	  (≥1) 0·∙35	  (0·∙27	  to	  0·∙43) <0·∙001 
 Age	  (41-­‐51) 0·∙11	  (0·∙016	  to	  0·∙21) 0·∙023 
 Age	  (52-­‐90) 0·∙23	  (0·∙13	  to	  0·∙33) <0·∙001 
    
rH2/57 Vaccination	  (≥1) 0·∙12	  (-­‐0·∙10	  to	  0·∙33) 0·∙267 
 Age	  (41-­‐51) 0·∙53	  (0·∙28	  to	  0·∙78) <0·∙001 
 Age	  (52-­‐90) 1·∙12	  (0·∙86	  to	  1·∙38) <0·∙001 
    
rH3/99 Vaccination	  (≥1) 0·∙19	  (0·∙070	  to	  0·∙31) 0·∙002 
 Age	  (41-­‐51) -­‐0·∙11	  (-­‐0·∙26	  to	  0·∙038) 0·∙145 
 Age	  (52-­‐90) -­‐0·∙25	  (-­‐0·∙40	  to	  -­‐0·∙095) 0·∙002 
    
rH1pdm/09 Vaccination	  (≥1) 0·∙20	  (0·∙11	  to	  0·∙29) <0·∙001 
 Age	  (41-­‐51) 0·∙15	  (0·∙048	  to	  0·∙26) 0·∙004 
 Age	  (52-­‐90) 0·∙14	  (0·∙033	  to	  0·∙25) 0·∙011 
    
rH4/56 Vaccination	  (≥1) 0·∙062	  (-­‐0·∙14	  to	  0·∙26) 0·∙543 
 Age	  (41-­‐51) 0·∙34	  (0·∙096	  to	  0·∙58) 0·∙006 
 Age	  (52-­‐90) 0·∙20	  (-­‐0·∙055	  to	  0·∙45) 0·∙125 
    
rH5/04 Vaccination	  (≥1) 0·∙28	  (0·∙16	  to	  0·∙40) <0·∙001 
 Age	  (41-­‐51) 0·∙35	  (0·∙21	  to	  0·∙49) <0·∙001 
 Age	  (52-­‐90) 0·∙33	  (0·∙18	  to	  0·∙48) <0·∙001 
    
rH7/79 Vaccination	  (≥1) -­‐0·∙015	  (-­‐0·∙086	  to	  0·∙055) 0·∙667 
 Age	  (41-­‐51) -­‐0·∙041	  (-­‐0·∙13	  to	  0·∙044) 0·∙347 
 Age	  (52-­‐90) -­‐0·∙065	  (-­‐0·∙15	  to	  0·∙020) 0·∙148 
    
rH12/76 Vaccination	  (≥1) 0·∙11	  (-­‐0·∙0037	  to	  0·∙23) 0·∙058 
 Age	  (41-­‐51) -­‐0·∙027	  (-­‐0·∙16	  to	  0·∙11) 0·∙704 
 Age	  (52-­‐90) -­‐0·∙11	  (-­‐0·∙25	  to	  0·∙034) 0·∙052 
Reference	  age:	  0-­‐40;	  rHAs,	  recombinant	  hemagglutinin.	  	  
 
Table 4. Analysis of neutralizing titers with respect to age group and vaccination 
status. 
 
 
Table	  4.	  Multivariable	  regressions	  analyzing	  neutralizing	  titers	  
	  -­‐log(IC50)	  in	  relation	  with	  vaccination	  and	  age	  
	   	   	   	  
Virus Characteristics Regression	  Coefficient	  (95%	  CI) 
p-­‐value 
H1/34 Vaccination	  (≥1) 0·∙27	  (0·∙15	  to	  0·∙39) <0·∙001 
 Age	  (41-­‐51) 0·∙017	  (-­‐0·∙12	  to	  0·∙16) 0·∙809 
 Age	  (52-­‐90) 0·∙099	  (-­‐0·∙048	  to	  0·∙25) 0·∙185 
 
   
H1/07 Vaccination	  (≥1) 0·∙66	  (0·∙47	  to	  0·∙85) <0·∙001 
 Age	  (41-­‐51) -­‐0·∙073	  (-­‐0·∙30	  to	  0·∙15) 0·∙524 
 Age	  (52-­‐90) -­‐0·∙074	  (-­‐0·∙31	  to	  0·∙16) 0·∙536 
 
   
H2/57 Vaccination	  (≥1) -­‐0·∙085	  (-­‐0·∙18	  to	  0·∙013) 0·∙089 
 Age	  (41-­‐51) 0·∙46	  (0·∙34	  to	  0·∙57) <0·∙001 
 Age	  (52-­‐90) 0·∙96	  (0·∙83	  to	  1·∙082) <0·∙001 
    
H3/68 Vaccination	  (≥1) 0·∙022	  (-­‐0·∙094	  to	  0·∙14) 0·∙708 
 Age	  (41-­‐51) 0·∙85	  (0·∙71	  to	  0·∙99) <0·∙001 
 Age	  (52-­‐90) 0·∙73	  (0·∙59	  to	  0·∙88)	  	   <0·∙001 
 
   
H3/07 Vaccination	  (≥1) 0·∙40	  (0·∙106	  to	  0·∙69)	   0·∙008 
 Age	  (41-­‐51) 0·∙094	  (-­‐0·∙26	  to	  0·∙45) 0·∙597 
 Age	  (52-­‐90) -­‐0·∙096	  (-­‐0·∙46	  to	  0·∙27) 0·∙604 
    
H4/56 Vaccination	  (≥1) 0·∙034	  (-­‐.058	  to	  .13) 0·∙464 
 Age	  (41-­‐51) 0·∙085	  (-­‐.026	  to	  .20) 0·∙133 
 Age	  (52-­‐90) 0·∙14	  (.021	  to	  .25) 0·∙021 
 
   
H5/04 Vaccination	  (≥1) 3·∙43	  (0·∙76	  to	  6·∙10) 0·∙012 
 Age	  (41-­‐51) 0·∙71	  (-­‐2·∙50	  to	  3·∙92) 0·∙664 
 Age	  (52-­‐90) 0·∙39	  (-­‐2·∙94	  to	  3·∙72) 0·∙818 
    
H7/79 Vaccination	  (≥1) -­‐1.059	  (-­‐4·∙091	  to	  1·∙97) 0·∙492 
 Age	  (41-­‐51) 0·∙71	  (-­‐2·∙95	  to	  4·∙34) 0·∙708 
 Age	  (52-­‐90) 3·∙32	  (-­‐0·∙64	  to	  7·∙11) 0·∙085 
Reference	  age:	  0-­‐40.	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Supplementary Figures 
 
Suppl. Figure 1:  
Figure 1. Prevalence and distribution of homo- and heterosubtypic serum antibodies.  
 
(A) Serum antibody reactivities against the indicated immobilized recombinant hemagglutinin were 
assessed by ELISA and displayed as the logarithm of the reciprocal serum dilution giving a half-
maximal effective dose -log(EC50). (B) Percentage of participants displaying ELISA signals greater 
than half-maximal value against the indicated HA subtype at a serum dilution of either 1 in 30 (bold-
faced bars) and 1 in 90 (open-faced bars). (C) Neutralizing serum antibody titer to human and avian 
virus isolates plotted as the logarithm of the reciprocal serum dilution giving half-maximal inhibition 
(-logIC50). (D) Percent neutralization of H5/57 and H7/79 viruses at a serum dilution of 1 in 90 for 
viruses whose IC50 could not be estimated. Neutralization was tested at a multiplicity of infection of 
2-6. Boxplots in (A), (C) and (D) indicate median and interquartile ranges (IQR), whiskers include 
lower or upper quartile ± 1·5 x IQR. 
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Suppl. Figure 2: Linear regression of binding and neutralizing antibody titers plotted 
against age in vaccinated and non-vaccinated donors. 
 
(A) Binding titers. The -log(EC50) values for rH3/99, but not for rH1/34 or rH2/57, were lower in 
more seasoned individuals. Smoothing discovers steep increase of -log(EC50) around age 40 for 
rH2/57. Highest -log(EC50) titers to rH3/99 are depicted in the age group of the 21-27 years old 
individuals. Values are shown as logarithm of the reciprocal serum dilution in correlation with age.  
(B) Neutralizing titers. Neutralizing titers to H1/34 (vaccinated), H2/57 (vaccinated and non-
vaccinated) and H3/68 (vaccinated and non-vaccinated) increased with increasing age. -log(IC50) to 
H1/07 (vaccinated) decreased with increasing age. Remaining subtypes do not show slopes different 
from zero. Values are shown as logarithm of the reciprocal serum dilution giving a half-maximal 
inhibitory concentration, and as inhibition percentage against H5/57 and H7/79 at a serum dilution 
of 1 in 90. Blue triangles and lines represent the vaccinated, black squares and lines the non-
vaccinated cohort. Grey shaded areas indicate the confidence band. Significance codes (testing the 
slope being different from zero): *** p<0·001, ** p<0·01, * p<0·05. 
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Suppl. Figure 3: Linear regression and smoothing of binding antibody titers to virions 
of H7/79 directly coated to ELISA plates 
 
Left panels: linear regressions; right panels: loess smoothing. 
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Supplementary Tables 
 
Supplementary Table 1. Prevalence and distribution of homo- and heterosubtypic 
serum antibodies. 
 
 
S1.	  Prevalence	  and	  distribution	  of	  homo-­‐	  and	  heterosubtypic	  serum	  antibodies.	  
	  
rHAs	  	   -­‐log(EC50)Median	  [IQR]	  
rH1/34	   2·∙36	  [2·∙06	  to	  2·∙57]	  
rH1/pdm09	   1·∙48	  [1·∙27	  to	  1·∙73]	  
rH2/57	   1·∙06	  [0·∙69	  to	  1·∙51]	  
rH3/99	   3·∙28	  [2·∙98	  to	  3·∙64]	  
rH4/56	   1·∙55	  [1·∙18	  to	  1·∙91]	  
rH5/04	   1·∙50	  [1·∙21	  to	  1·∙88]	  
rH7/79	   1·∙65	  [1·∙48	  to	  1·∙83]	  
rH12/76	   2·∙23	  [1·∙91	  to	  2·∙51]	  
	   	  
	   	  
	   	  
HAs	  	   -­‐log(IC50)Median	  [IQR]	  
H1/34	   3·∙00	  [2·∙71	  to	  3·∙28]	  
H1/07	   2·∙47	  [2·∙015	  to	  3·∙21]	  
H2/57	   2·∙42	  [2·∙16	  to	  2·∙81]	  
H3/68	   2·∙67	  [2·∙23	  to	  3·∙21]	  
H3/07	   2·∙50	  [2·∙13	  to	  2·∙94]	  
H4/56	   1·∙94	  [1·∙74	  to	  2·∙07]	  
H5/04	  *	   2·∙50	  [-­‐1·∙00	  to	  6·∙50]	  
H7/79	  *	   11·∙50	  [4·∙50	  to	  21·∙00]	  
rHAs,	  recombinant	  hemagglutinin.	  
*	  [%	  neutralization	  at	  1/90]	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Supplementary Table 2. Linear regressions analyzing relation of binding vs. 
neutralizing titers. 
 
 
 
 
S2.	  Linear	  regressions	  analyzing	  relation	  of	  binding	  titers	  -­‐log(EC50)	  vs.	  neutralizing	  titers	  -­‐log(IC50)	  
	   	   	  
Strains	  vs.	  rHAs Regression	  Coefficient	  β	  
(95%	  CI) 
p-­‐value 
H1/07	  vs.	  rH1/pdm09 0·∙12	  (0·∙068	  to	  0·∙16) <0·∙001 
H1/34	  vs.	  rH1/34 0·∙29	  (0·∙20	  to	  0·∙38) <0·∙001 
H1/34	  vs.	  rH1/pdm09 0·∙15	  (0·∙069	  to	  0·∙24) <0·∙001 
H1/07	  vs.	  rH1/34 0·∙17	  (0·∙11	  to	  0·∙22) <0·∙001 
H2/57	  vs.	  rH2/57 0·∙69	  (0·∙53	  to	  0·∙85) <0·∙001 
H3/68	  vs.	  rH3/99 -­‐0·∙062	  (-­‐0·∙15	  to	  0·∙026) 0·∙168 
H3/07	  vs.	  rH3/99 0·∙14	  (0·∙095	  to	  0·∙18) <0·∙001 
H4/56	  vs.	  rH4/56 0·∙52	  (0·∙29	  to	  0·∙74) 0·∙011 
H5/04	  vs.	  rH5/04 0·∙0074	  (0·∙0017	  to	  0·∙013) <0·∙05 
H7/79	  vs.	  rH7/79 0·∙000088	  (-­‐0·∙0025	  to	  0·∙0027) 0·∙948 
H7/79	  vs.	  H7vir/79 0·∙0024	  (-­‐0·∙00018	  to	  0·∙0050) 0·∙068 
 
Reported are the results of linear regression of binding vs. neutralizing titers. The p-value is reported 
for the null hypothesis:  β = 0.  
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Supplementary methods 
Study design and participants 
The ethics committee of the University Hospital Zurich approved the study (ref. no. EK-17-42) and 
written informed consent was obtained from all study participants. Enrollment ran for the most part 
from October 20, 2009 to October 30, 2009 (before the arrival of the swine-flu pandemic virus 
H1pdm/09 in Switzerland). A minor portion (n=13) of blood samples was collected one year before. 
All samples were obtained before the start of the seasonal vaccine campaign 17 (5·28%) donors who 
were enrolled in the 2009 Novartis clinical trial for the H1/pdm09 vaccine, were excluded from our 
analysis [1]. 
This included age, categories of the number of approximate previous vaccinations, influenza exposure 
history (including potential contact to fowl plague infected poultry), enrollment in the 2009 Novartis 
vaccine trial for the H1pdm/09 vaccine and recent travel to rural regions in southeastern Asia. The 
number of influenza infections was subjectively apprised as influenza-like disease lasting for more 
than five days, and is not supported by laboratory data. 
Translation of the questionnaire filled out at the time of the blood drawing: 1. How	  often	  in	  your	  life	  do	  you	  think	  you	  have	  had	  an	  influenza	  infection?	  With	  influenza	  infection	  we	  refer	  to	  all	  ‘flus’	  that	  lasted	  longer	  than	  4	  days,	  that	  were	  accompanied	  by	  severe	  malaise	  and	  high	  fever,	  and	  that	  left	  you	  bedbound	  for	  more	  than	  3-­‐4	  days.	  	  2. How	  often	  have	  you	  been	  vaccinated	  against	  influenza?	  3. Have	  you	  already	  been	  vaccinated	  against	  influenza	  this	  year?	  4. Have	  you	  been	  vaccinated	  against	  the	  swine	  flu?	  5. Have	  you	  been	  diagnosed	  with	  swine	  flu	  and	  did	  a	  laboratory	  confirm	  this	  diagnosis?	  6. Have	  you	  been	  infected	  by	  swine	  flu?	  7. Did	  you	  stay	  longer	  than	  3	  weeks	  in	  rural	  areas	  of	  Southeast	  Asia?	  	  8. Have	  you	  knowingly	  been	  in	  contact	  with	  influenza	  infected	  fowl	  or	  poultry?	  Avian	  influenza	  is	  also	  referred	  to	  as	  ‘fowl	  plague’.	  
Statistical analyses 
STATA 12 SE (StataCorp, College Station, TX) and R (2.15.2) software were used for association and 
correlations studies. GraphPad Prism 6 and Adobe Illustrator CS 5.1 were used for generation of 
blots. 
Vaccination analysis (figure 2 and 3) was performed using two-sample t tests, participant numbers 
were as follows: 0 vaccinations (n=104), ≥1 vaccination (n=169) and missing declaration (n=32). 
Influenza episodes analyses were studied using simple and linear regression; 0 episodes (n=33), ≥1 
episodes (68), ≥1 episodes and vaccinations (n=169) these were excluded from the episode study and 
missing declaration (n=35) data not shown. 
Age categories were binned into: 0-40 y (n=184), 41-51 y (n=65) and 52-90 (n=56). 
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Multivariable analyses were performed using multiple linear regressions. 
Robust linear regressions in figures 4-7 were computed with rlm (MASS package), smoothing with 
loess (stats package) and displayed with ggplot2. Smoothing is noisier in proximity of the endpoints. 
Since the smoothing is done on less data, few points can influence the estimate heavily. For this 
reason the confidence regions grow at the borders, and one must be cautious in not over interpreting 
this behavior. 
Regression analysis of the full model was performed with glm (stats package). 
In a first analysis, linear regression was performed separately on vaccinated and non-vaccinated 
donors with the model: binding titer = intercept  +  α × age. By estimating the age effect separately, 
potential distortions induced by repetitive trivalent inactivated influenza vaccinations (TIV) could be 
assessed. 
Including the vaccination status as a covariate allowed us to simultaneously estimate the effect of age 
and vaccination and a potential interaction between them. To this end, we started estimating the 
coefficients of the full model: binding titer = intercept  +  α × age  +  β × vaccination  +  γ × age × 
vaccination, where the age is given in years and vaccination is a binary dummy variable. 
In order to avoid over fitting, the complexity of the model was iteratively reduced by removing the 
coefficients not significantly different from zero and re-estimating the others. We required the p-
value for the regression coefficients to be lower than 1% in order to keep them in the model. This 
informal calibration of the significance threshold also constitutes an attempt to address the multiple 
testing issue [2]. 
Scripts used for this study are available at https://github.com/ozagordi/FluAbs 
Blood samples 
Full blood was allowed to coagulate at RT for at least 30 min before serum was collected by 
centrifugation (at 20 °C at 2’500 x g for 15 min), and stored in 1mL aliquots at -80 °C. Before use, 
aliquots of sera were thawed and heat inactivated at 56 °C for 30 min and supplemented with 0.1% 
NaN3 as preservative. Heat inactivated serum was stored at 4 °C.  
 
Cells 
Madin Darby canine kidney (MDCK) cells were purchased from the American Type Culture 
Collection (ATCC®: CCL-34™) and used for all cell-based assays. Cells were maintained in 
Dulbecco's Modified Eagle Medium (DMEM) supplemented with heat inactivated 10% fetal bovine 
serum, and 50 U/mL penicillin and 50 µg/mL streptomycin. 
Virus preparation and concentration 
Influenza viruses were propagated either on MDCK or in d11 embryonated hen eggs, and harvested 
24 to 48 h (MDCK cells) or 48 h (eggs) post infection. For ELISA using virions from 
A/FPV/Bratislava/79(H7N7) (H7vir/79), virus was collected from cell supernatant by 
ultracentrifugation through a 32% sucrose cushion (2 h at 4 °C at 28’000 rpm; swing out rotor 
SW28). 
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Generation of recombinant HA 
Recombinant HAs (rHAs) were obtained from following strains: A/Puerto Rico/8/34(H1N1) 
(rH1/34), A/California/04/09(H1N1) (rH1pdm/09), A/Japan/305/57(H2N2) (rH2/57), 
A/Moscow/10/99(H3N2)(rH3/99), A/Duck/Czechoslovakia/56(H4N6) (rH4/56),  
A/Vietnam/1203/04(H5N1) (rH5/04), A/FPV/Bratislava/79(H7N7) (rH7/79) and  
A/Duck/Alberta/35/76 (H12N5) (rH12/76).  
The HA-constructs were either generated from viral RNA according to Hoffman or de novo synthesis 
according to the published sequence or by already cloned cDNAs received from other labs [3]. In 
brief, viral RNA was isolated from cell supernatant using RNeasy Mini Kit columns (Qiagen). 
Following reverse transcription using Superscript II reverse transcriptase (Invitrogen) and a forward 
primers specific for segment 4. Segment 4, containing the HA gene, was then amplified by PCR using 
segment 4-specific degenerated primer. After subcloning of the amplified cDNA into the pcDNA 3.1 
vector (Invitrogen) and sequencing, the ORF was modified for baculovirus expression as described in 
Stevens et al. [4]. 
rHAs, stabilized by a his-tagged trimerization domain, were expressed into the supernatant of 
Baculovirus infected SF9 cells at 28 °C and harvested 4 d post infection. Soluble HA was recovered 
from the cell supernatant by metal affinity chromatography using NiNTA beads (GE Healthcare).[5] 
Fractions containing HAs were pooled and concentrated with Centrifugal Filter Unit (Ultra-15 
Ultracel-10 membrane, Amicon) proteolytically processed into HA1 and HA2 with 10 U/µg HA of 
TPCK-treated trypsin (Sigma Aldrich) at RT for 1 h. Trypsin was removed by size exclusion 
chromatography on Superdex S200 slurry (GE Healthcare) and fractions containing HA trimers were 
collected and concentrated. 
ELISA 
96-well Corning® half-area polystyrene high binding microplates (Costar) were coated with 25 µl of 1 
µg/mL HA in PBS at 4 ⁰C for 64 h. Coated plates were then blocked with 3% BSA in PBS for at least 1h 
at RT. Sera were titrated in 1% BSA/PBS, and allowed to bind for 1 h. After washing with 0.01% 
Tween/TBS, bound serum IgG was detected with HRPO-coupled a goat anti-human fab-HRP 
antibodies (Jackson Immuno). The assay was developed for 12 min using 50 µL TMB (2 mg/mL) / 
H2O2 (5 µL/mL) in 0.1 M NaH2PO4 * H2O as a chromogenic substrate before the reaction was stopped 
by the addition of 50 µL 2 N H2SO4. After determining absorption at 450 nm, the serum dilutions 
giving half maximal absorbance was determined by non-linear regression of the measured OD values 
to the logarithmized serum concentration using the Hill-Curve as equation template. If no fit could be 
obtained, i.e. when an individual sample did provide sufficient data points for an accurate fit, top and 
bottom values were constrained to the corresponding average values determined over the whole assay 
fitting data to sigmoid dose response curves (variable slope) using GraphPad Prism 5 and 6 and Excel 
2007 (Microsoft).  
Neutralization assay 
Strains used for neutralization assays were A/Puerto Rico/8/34(H1N1) (H1/34), 
A/Brisbane/59/07(H1N1) (H1/07), A/Singapore/1/57(H2N2) (H2/57), 
A/Brisbane/10/2007(H3N2) (H3/07), A/Hong Kong/68(H3N2) (H3/68), 
A/Duck/Czechoslovakia/56(H4N6) (H4/56), rg-A/Chicken/Vietnam/C58/2004(H5N3) [R] (H5/04) 
and A/FPV/Bratislava/79(H7N7) (H7/79).  
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Sera were titrated and combined with virus corresponding to an MOI of 2 to 6 in 20 mM Hepes 
supplemented DMEM containing 0.2 % BSA (DMEM/BSA) with the help of a semi-automated 
pipetting system (BioTek Precision). The virus-sera mix was incubated at 37 °C for 1 h and 
transferred to the cells, where non-neutralized virus was allowed to infect cells for 1 h at 37 °C. The 
virus-serum mix was then removed, plates washed with PBS and DMEM/BSA added. Viral protein 
synthesis was allowed to proceed for 6-7 h before cells were fixed and permeabilized with 100% 
methanol. Cells were then stained with FITC-labeled anti-NP antibody (3 µg/ml), H16-L10-4R5 
(ATCC No. HB-65™), in PBS containing 1% BSA at 4 °C over night, followed by nuclear staining using 
Hoechst dye (Molecular probes). Fluorescence or both FITC and Hoechst were measured by a Perkin 
Elmer plate reader at 16 different locations in each well to account for variation in the local cell 
densities. The average from the individual measuring points was used to calculate the half maximal 
inhibitory concentration (IC50) were determined using the same approach as described for EC50.  
For H5 and H7 low heterosubtypic neutralizing activity was found in sera that prevented computation 
of the logIC50. Instead, the inhibition percentage at the first dilution (1 in 90) was taken as 
comparative value. 
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